Autonomix Medical Stock Forecast

Stock Price Forecast

The 1 analyst with a 12-month price forecast for Autonomix Medical stock has a target of 5, which predicts a 173.22% increase from the current stock price of 1.83.

Price Target: $5 (+173.22%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$5.00	$5.00	$5.00	$5.00
Change	+173.22%	+173.22%	+173.22%	+173.22%

* Price targets were last updated on Apr 29, 2025.

Analyst Ratings

According to 1 stock analyst, the rating for Autonomix Medical is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jun '25	Jul '25
Strong Buy	1	1
Buy	0	0
Hold	0	0
Sell	0	0
Strong Sell	0	0
Total	1	1

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Anthony Vendetti Maxim Group	Maxim Group	Strong Buy Initiates $5	Strong Buy	Initiates	$5	+173.22%	Apr 29, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

Revenue Next Year

n/a

EPS This Year

-4.38

from -6.46

EPS Next Year

-3.77

from -4.38

Fiscal Year	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027	FY 2028
Period Ending	Mar 31, 2022	Mar 31, 2023	Mar 31, 2024	Mar 31, 2025	Mar 31, 2026	Mar 31, 2027	Mar 31, 2028
Revenue	-	-	918.00K
Revenue Growth	-	-	-	-	-	-	-
EPS	-123.94	-3.31	-14.82	-6.46	-4.38	-3.77	-5.14
EPS Growth	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	4	4	3

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027	2028
High	n/a	n/a	945,000
Avg	n/a	n/a	918,000
Low	n/a	n/a	882,000

Revenue Growth

Revenue Growth	2026	2027	2028
High	-	-	-
Avg	-	-	-
Low	-	-	-

EPS Forecast

EPS	2026	2027	2028
High	-3.53	-2.42	-5.29
Avg	-4.38	-3.77	-5.14
Low	-5.12	-4.99	-4.94

EPS Growth

EPS Growth	2026	2027	2028
High	-	-	-
Avg	-	-	-
Low	-	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.